Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661356 | 1.00 | MAPT (0.38) | MAPTKDM4EKMT2AATMCYP2D6 | |
| SCHEMBL659836 | 1.00 | MAPT (0.38) | MAPTKDM4EKMT2AATMCYP2D6 | |
| SCHEMBL691260 | 0.92 | KDM4E (0.50) | MAPTKDM4EKMT2AATMCYP2D6 | |
| SCHEMBL660798 | 0.92 | KDM4E (0.50) | MAPTKDM4EKMT2AATMCYP2D6 | |
| SCHEMBL658030 | 0.92 | KDM4E (0.50) | MAPTKDM4EKMT2AATMCYP2D6 | |
| SCHEMBL363474 | 0.91 | GABRP (0.41) | MAPTKDM4EKMT2AATMCYP2D6 | |
| SCHEMBL17732326 | 0.90 | KDM4E (0.36) | MAPTKDM4EKMT2AATMCYP2D6 | |
| SCHEMBL17712561 | 0.90 | KDM4E (0.36) | MAPTKDM4EKMT2AATMCYP2D6 | |
| SCHEMBL7830312 | 0.90 | KDM4E (0.36) | MAPTKDM4EKMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL16054755 | 0.90 | GABRP (0.39) | MAPTKDM4EKMT2AATMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RES INC (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2016-09-29 | — | — | US | disclosed |
| US-9393246-B2 | 4,6-disubstituted pyrimidines as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-9296704-B2 | Substituted pyrimidines as protein kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150328223-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2015-11-19 | — | — | US | disclosed |
| US-9040541-B2 | 4,6-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140303165-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2014-10-09 | — | — | US | disclosed |
| EP-2776431-A1 | 2-OXO-OXAZOLIDIN-3,5-DIYL ANTIBIOTIC DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2014-09-17 | — | — | EP | disclosed |
| US-8748606-B2 | 4,6-diaminopyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| EP-2214486-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Avila Therapeutics, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2010-07-01 | — | — | US | disclosed |
| WO-2010051085-A1 | 7-HYDROXY-BENZOIMIDAZOLE-4-YL-METHANONE DERIVATIVES AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2010-05-06 | — | — | WO | disclosed |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| WO-2009051822-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| CN-1882347-A | AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2006-12-20 | — | — | CN | disclosed |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311780-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MAPT 1888/4885KDM4E 3792/4885KMT2A 3318/4885 |
| US-20100168123-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | MAPT 3331/4885KDM4E 2590/4885KMT2A 2166/4885 |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | MAPT 3747/4885KDM4E 581/4885KMT2A 1366/4885 |
| US-20090137588-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MAPT 1888/4885KDM4E 3792/4885KMT2A 3318/4885 |
| US-20160279127-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MAPT 1888/4885KDM4E 3792/4885KMT2A 3318/4885 |
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MAPT 1888/4885KDM4E 3792/4885KMT2A 3318/4885 |
| US-20150328223-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MAPT 1888/4885KDM4E 3792/4885KMT2A 3318/4885 |
| US-20140303165-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MAPT 1888/4885KDM4E 3792/4885KMT2A 3318/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | MAPT 3331/4885KDM4E 2590/4885KMT2A 2166/4885 |
| US-20050130954-A1 | Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline | MTOR, CDK2, CLK2 | MAPT 3207/4885KDM4E 1872/4885KMT2A 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.